Development of Polymeric Nanopaclitaxel and Comparison with Free Paclitaxel for Effects on Cell Proliferation of MCF-7 and B16F0 Carcinoma Cells

Abstract

Paclitaxel is hydrophobic in nature and is recognized as a highly toxic anticancer drug, showing adverse effects in normal body sites. In this study, we developed a polymeric nano drug carrier for safe delivery of the paclitaxel to the cancer that releases the drug in a sustained manner and reduces side effects. N-isopropylacrylamide/ vinyl pyrrolidone (NIPAAm/VP) nanoparticles were synthesized by radical polymerization. Physicochemical characterization of the polymeric nanoparticles was conducted using dynamic light scattering, transmission electron microscopy, scanning electron microscopy and nuclear magnetic resonance, which confirmedpolymerization of formulated nanoparticles. Drug release was assessed using a spectrophotometer and cell viability assays were carried out on the MCF-7 breast cancer and B16F0 skin cancer cell lines. NIPAAm/ VP nanoparticles demonstrated a size distribution in the 65-108 nm range and surface charge measured -15.4 mV. SEM showed the nanoparticles to be spherical in shape with a slow drug release of ~70% in PBS at 38°C over 96 h. Drug loaded nanoparticles were associated with increased viability of MCF-7 and B16F0 cells in comparison to free paclitaxel. Nano loaded paclitaxel shows high therapeutic efficiency by sustained release action for the longer period of time, i increasing its efficacy and biocompatibility for human cancer therapy. Therefore, paclitaxel loaded (NIPAAm/VP) nanoparticles may provide opportunities to expand delivery of the drug for clinical selection.

Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells

“…SEM analysis showed that paxlitaxel-loaded nanoparticles were like good solid balls. Multiple studies showed that many chemotherapeutics could inhibit the proliferation and induce cell apoptosis, such as paclitaxel (Yadav et al, 2014;Lim et al, 2015;Lin et al, 2015). By promoting microtubulin to form into canaliculus and suppressing depolymerization, paclitaxel-loaded drugs can lead to aberrant arrangement of microtubule fasolculus, formation of asteriform, abnormal function of spindle apparatus and inhibition of cell mitosis, thus inducing apoptosis and inhibiting cell proliferation (Pan et al, 2013).…”

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

“…Breast cancer remains a significant problem for global health as it is one of the most common cause of tumorrelated death world-wide (Fouz et al, 2013;Engin et al, 2013;Sedighi et al, 2013;Zhu et al, 2013;Wu et al , 2014;Cabuk et al, 2014;Chin et al, 2014;Fouladi et al, 2014;Majeed et al, 2014;Gogia et al, 2014;Liu et al, 2014;Louisa et al, 2014;Moazzezy et al, 2014;Niu et al, 2014;Rizalar et al, 2014;Sipetic-Grujicic et al, 2014;Prajoko et al, 2014;Inanc et al, 2014;Varol et al, 2014;Yadav et al, 2014). Pemetrexed is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide ormyltransferase.…”

Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles

“…Thus this effect makes drug loaded nano-carriers to concentrate in tumor sites (Maeda et al, 2000;Kingsley et al, 2006;Vicent and Duncan, 2006;Yadav et al, 2014). Among particulate drug carriers, polymeric nanoparticles exhibit suitable characteristics for encapsulation of many drugs (Torchilin, 2007).…”